Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A

References

• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Data & statistics on hemophilia. [cited 2019 April 6]. Available from: https://www.cdc.gov/ncbddd/hemophilia/data.html.
   Google Scholar
• World Federation of Hemophilia.World Federation of Hemophilia report on the annual global survey 2017. Montreal, Quebec. [cited 2019 Apr 5]. Available from: http://www1.wfh.org/publications/files/pdf-1714.pdf.
   Google Scholar
• Centers for Disease Control and Prevention. What is Hemophilia? 2018 [updated 2018 Sep 6; cited 2019 July 23]. Available from: https://www.cdc.gov/ncbddd/hemophilia/facts.html.
   Google Scholar
• Melchiorre D, Manetti M, Matucci-Cerinic M. Pathophysiology of hemophilic arthropathy. J Clin Med. 2017;6(7):63.
   PubMed Web of Science ®Google Scholar
• Knobe K, Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb. 2011;1(1):51–59.
   PubMedGoogle Scholar
• O’Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017; 12(1):106.
   PubMed Web of Science ®Google Scholar
• Curtis R, Baker J, Riske B, et al. Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status. Am J Hematol. 2015;90(Suppl 2):S11–S6.
   PubMedGoogle Scholar
• Croteau SE, Cheng D, Cohen AJ, et al. Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. Haemophilia. 2019;25(4):668–675.
   PubMed Web of Science ®Google Scholar
• Collins PW, Blanchette VS, Fischer K ,et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3):413–420.
   PubMed Web of Science ®Google Scholar
• Berntorp E, Dolan G, Hay C, et al. European retrospective study of real-life haemophilia treatment. Haemophilia. 2017;23(1):105–114.
   PubMed Web of Science ®Google Scholar
• Duncan N, Kronenberger WG, Krishnan S, et al. Adherence to prophylactic treatment in hemophilia A as measured using the Veritas-PRO and annual bleed rate (ABR). Value Health. 2014;17(3):A230.
   Web of Science ®Google Scholar
• Krishnan S, Vietri J, Furlan R, et al. Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey. Haemophilia. 2015 ;21(1):64–70.
   PubMed Web of Science ®Google Scholar
• Shrestha A, Eldar-Lissai A, Hou N, et al. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia. 2017;23(4):e267–e275.
   PubMed Web of Science ®Google Scholar
• Zhou ZY, Koerper MA, Johnson KA, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015;18(6):457–465.
   PubMed Web of Science ®Google Scholar
• Hemlibra (emicizumab-kxwh) injection. Prescribing information. South San Francisco, CA: Genentech, Inc; 2018.
   Google Scholar
• BioMarin eyes 2019 FDA filing for haemophilia A gene therapy [Internet]. 2018 [cited 2019 Mar 1]. Available from: http://www.pmlive.com/pharma_news/biomarin_eyes_2019_fda_filing_for_haemophilia_a_gene_therapy_1259266.
   Google Scholar
• Single-arm study to evaluate the efficacy and safety of valoctocogene roxaparvovec in hemophilia A patients (BMN 270-301). [cited 2019 Nov 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT03370913.2017.
   Google Scholar
• Ramsey SD, Willke RJ, Glick H, et al. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. Value Health. 2015;18(2):161–172.
   PubMed Web of Science ®Google Scholar
• Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A. N Engl J Med. 2020;382(1):29–40.
   PubMed Web of Science ®Google Scholar
• Krijkamp EM, Alarid-Escudero F, Enns EA, et al. Microsimulation modeling for health decision sciences using R: a tutorial. Med Decis Making. 2018;38(3):400–422.
   PubMed Web of Science ®Google Scholar
• Pettersson H, Ahlberg Å, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res. 1980;(149):153–159.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
   PubMed Web of Science ®Google Scholar
• Rangarajan S, Walsh L, Lester W, et al. AAV5–factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519–2530.
   Google Scholar
• Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2(14):1792–1798.
   PubMed Web of Science ®Google Scholar
• Bienaime JH. Valactogene Roxaparvovec Phase 2 and Phase 3 Update 2019 [updated 2019 May 28; cited 2019 May 28]. Available from: https://investors.biomarin.com/events-presentations?item=58.
   Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without Inhibitors. N Engl J Med. 2018;379(9):811–822.
   PubMed Web of Science ®Google Scholar
• den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011;17(6):849–853.
   PubMed Web of Science ®Google Scholar
• den Uijl IE, Fischer K, Van Der Bom JG, et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia. 2011;17(1):41–44.
   PubMed Web of Science ®Google Scholar
• Arias E, Xu J, Kochanek KD. United States life tables, 2016. Natl Vital Stat Rep. 2019;68(4):1–66.
   PubMedGoogle Scholar
• Mejia ‐Carvajal C, Czapek E, Valentino L. Life expectancy in hemophilia outcome. J Thromb Haemost. 2006;4(3):507–509.
   PubMed Web of Science ®Google Scholar
• Lofqvist T, Nilsson IM, Berntorp E, et al. Haemophilia prophylaxis in young patients–a long-term follow-up. J Intern Med. 1997;241(5):395–400.
   PubMed Web of Science ®Google Scholar
• Fischer K, van Hout BA, van der Bom JG, et al. Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiol. 2002;43(5):528–532.
   PubMed Web of Science ®Google Scholar
• Earnshaw SR, Graham CN, McDade CL, et al. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015;21(3):310–319.
   PubMed Web of Science ®Google Scholar
• Fischer K, Pouw ME, Lewandowski D, et al. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica. 2011;96(5):738–743.
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544.
   PubMed Web of Science ®Google Scholar
• Fryar CD, Gu Q, Ogden CL, et al. Anthropometric reference data for children and adults: United States, 2011–2014. Vital Health Stat. 2016;3:1–46.
   Google Scholar
• U.S. Department of Health Human Services. Using appropriate price indices for expenditure comparisons. Agency for Healthcare Research and Quality. 2014. [cited 2019 Jul 23]. Available from: https://meps.ahrq.gov/about_meps/Price_Index.shtml.
   Google Scholar
• U.S. Bureau of Economic Analysis. Personal Consumption Expenditures: Chain-type Price Index [PCEPI]. 2019. [cited 2019 Jul 23]. Available from: https://fred.stlouisfed.org/series/PCEPI.
   Google Scholar
• America’s Health Insurance Plans (AHIP). National Comparisons of Commercial and Medicare Fee-For-Service Payments to Hospitals. Data Brief. 2016.
   Google Scholar
• Rosas S, Buller LT, Plate J, et al. Total knee arthroplasty among medicare beneficiaries with hemophilia A and B is associated with increased complications and higher Costs. J Knee Surg. 2019.
   Google Scholar
• Fischer K, de Kleijn P, Negrier C, et al. The association of haemophilic arthropathy with health-related quality of life: a post hoc analysis. Haemophilia. 2016;22(6):833–840.
   PubMed Web of Science ®Google Scholar
• Neufeld EJ, Sidonio RF, Jr., O’Day K, et al. Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. J Med Econ. 2018;21(8):762–769.
   PubMed Web of Science ®Google Scholar
• Mazza G, O’Hara J, Carroll L, et al. The impact of haemophilia complications on health-related quality of life for adults with severe haemophilia. Value Health. 2016;19:A347–A766.
   Google Scholar
• Matza LS, Sapra SJ, Dillon JF, et al. Health state utilities associated with attributes of treatments for hepatitis C. Eur J Health Econ. 2015;16(9):1005–1018.
   PubMed Web of Science ®Google Scholar
• Ballal RD, Botteman MF, Foley I, et al. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Curr Med Res Opin. 2008;24(3):753–768.
   PubMed Web of Science ®Google Scholar
• Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. J Manag Care Spec Pharm. 2018;24(7):632–642.
   PubMed Web of Science ®Google Scholar
• Gold J. Miracle of hemophilia drugs comes at a steep price. 2018 [cited 2020 Jan 9]. Available from: https://www.npr.org/sections/health-shots/2018/03/05/589469361/miracle-of-hemophilia-drugs-comes-at-a-steep-price.
   Google Scholar
• Stephensen D, Tait RC, Brodie N, et al. Changing patterns of bleeding in patients with severe haemophilia A. Haemophilia. 2009;15(6):1210–1214.
   PubMed Web of Science ®Google Scholar
• Eloctate (Antihemophilic factor (recombinant), FC fusion protein). Prescribing information. Cambridge, MA: Sanofi Genzyme; 2017.
   Google Scholar
• Centers for Medicare & Medicaid Services. Medicare physician fee schedule. 2019 [cited 2019 Jul]. Available from: https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx.
   Google Scholar
• IBM Micromedex®. Red Book® Online 2019. 2019. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/
   Google Scholar
• Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule. 2019 [cited 2019 Jul]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html.
   Google Scholar